Thus, we are prompted to hypothesize that this anti-TNF-α agent may be beneficial not only in terms of disease severity, but also in terms of bone quality in patients with moderate-to-severe psoriasis by reducing serum adiponectin levels. This evidence concerns the gene ADIPOQ and psoriasis.